羅勒屬Biosolutions
成立一年
2000年階段
其他投資者 |活著缺失:羅勒屬Biosolutions的產品演示和案例研究
促進你的產品提供技術買家。
達到1000年代的買家使用CB的見解來確定供應商,演示產品,188bet游戏做出購買決定。
缺失:羅勒屬Biosolutions的產品&微分器
不要讓你的產品被跳過。買家使用我們的供應商排名名單公司和驅動(rfp)請求建議。
最新的羅勒屬Biosolutions新聞
2017年1月29日,
羅勒屬Biosolutions有限公司製藥醫療交易和聯盟資料價格250美元二二20美國東部時間2017年1月28日| BioPortfolio報告家裏»»»生物科學»最新消息主題羅勒屬Biosolutions有限公司製藥醫療交易和聯盟資料價格250美元總結羅勒屬Biosolutions羅勒屬是一個生命科學信息學公司提供解決方案與數據分析服務和BioIT谘詢服務。公司提供了生物分析,基因組數據分析服務,如生物信息學、基因表達、基因數據庫,基因分型,第二代測序,bioIT谘詢服務。它還提供了基因組學數據庫如BioExpress ToxExpress等等。公司的實驗室服務包括激光捕獲顯微解剖、核酸分離、基因外顯子和microrna的表達,基因拷貝數,克隆測序,qRTPCR服務和服務。羅勒屬還提供了診斷包。公司與科研院所合作和生物技術公司提供其服務。它運作在印度和美國。建邦者羅勒屬總部位於海德拉巴,納,印度。羅勒屬Biosolutions有限公司製藥醫療交易和聯盟為您提供全麵的數據和趨勢分析公司並購的MAs,夥伴關係和融資。報告提供詳細信息的並購,股票/債券發行、私募股權、風險融資和合作公司交易記錄的一個五年計劃。 The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News
羅勒屬Biosolutions常見問題(FAQ)
是什麼時候羅勒屬Biosolutions成立嗎?
羅勒屬Biosolutions成立於2000年。
羅勒屬哪裏Biosolutions總部嗎?
羅勒屬Biosolutions總部位於6樓,依賴經典,蓋。
什麼是羅勒屬Biosolutions的最新一輪融資?
羅勒屬Biosolutions的最新一輪融資是其他投資者。
誰是投資者的羅勒屬Biosolutions嗎?
投資者的羅勒屬Biosolutions包括國際金融公司、Kubera夥伴,Kubera跨境基金和無花果屬企業。
誰是羅勒屬Biosolutions的競爭對手?
競爭對手的羅勒屬Biosolutions包括Kiyatec WaferGen就近,ZyGEM,高溫凝膠分子診斷,ProteinSimple和10。
比較羅勒屬Biosolutions競爭對手
哈佛大學生物科學獲取和分配實驗室設備和產品的公司和機構在生命科學領域。
成功率來推動公共政策,建立一個網絡的行業領導者,創造獲得資本,引入幹教育項目,並創建價值觀取向的采購計劃。
Proteoplex Incyte基因組學和剝離是一個旨在為科學界提供關鍵功能基因組和蛋白質組學工具和服務領域的基因表達、蛋白表達和細胞化驗。蛋白質組學產品地址定義的主要障礙在細胞蛋白質的功能;如何迅速而廉價地測試數以千計的樣品存在一組特定的蛋白質。這種蛋白質產品將緊隨其後推出基因表達產品解決類似的基因組學市場的障礙;如何迅速而廉價地審問成千上萬的樣品與一組定義的重要基因。
KPS技術生產花青染料,在近紅外波段吸收和發出熒光。這些分子作為檢測單元是有用的,因為幾乎所有的有機材料包括生物組織是由近紅外光譜輻射滲透。感興趣的潛在應用是相當不同的但這些診斷的包括蛋白質標記、免疫測定、DNA測序。這些化合物的主要市場將儀器廠商。可以按照客戶要求定製包。
公司旨在提供強大的工具基於微電子技術的科學家參與基本的分子生物學研究。研究生物分子的行動“體外”培養細胞是藥物開發的基本步驟和基本生命科學。常規細胞內交付技術的高成本和耗時的過程,涉及使用大量的候選分子和一個隨機的解釋結果。由於一個組合的細胞和分子生物學與半導體技術公司開發出一種新技術克服這些限製。
固相生物科學公司收到STTR二期贈款項目的標題為:藥物發現鉛優化芯片的發展。他們獎資助在2009年美國複蘇與再投資法案和他們的項目將解決飼料複合鉛優化芯片的進一步發展和商業化(Multizyme芯片)高通量代鉛化合物的類似物加上細胞篩選生物活性的快速識別衍生品。這種能力直接影響藥物發現的一個關鍵瓶頸;即鉛化合物的高效優化與最優開發藥物藥理性質。固相生物科學公司提出把六個生物催化與生物活性化合物的藥理篩選提供快速識別特異性的目標,這是一個新的範例鉛優化。此外,Multizyme芯片平台將在相關行業,適合領導優化包括農用化學品、化妝品和藥妝品。固相技術將因此提高競爭力和效率的製藥、化妝品、化學工業,將作為豐富的新的和改進的商業產品。這項研究的廣泛影響是固相生物科學的進步將實現向創造更好、更安全的藥物,這些藥物降低開發成本,提高製藥行業的整體效率。固相將生成Multizyme芯片供製藥和生物技術公司,以促進他們的購買鉛優化程序,特別是那些涉及天然product-derived和複雜的合成小分子線索。低溫貯藏技術開發的第二階段將使芯片的銷售和chip-handling設備生產階段,並將允許固相技術平台的無縫滲透進入該公司的目標市場。 Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.
發現正確的解決方案為您的團隊
CB見解188bet游戏科技市場情報平台分析數百萬數據點在供應商、產品、合作關係,專利來幫助您的團隊發現他們的下一個技術解決方案。